

Level 2, 66 Hunter Street  
Sydney NSW 2000  
Tel: (61-2) 9300 3344  
Fax: (61-2) 9221 6333  
E-mail: [pnightingale@biotron.com.au](mailto:pnightingale@biotron.com.au)  
Website: [www.biotron.com.au](http://www.biotron.com.au)

29 April 2021

The Manager Companies  
ASX Limited  
20 Bridge Street  
Sydney NSW 2000

(2 pages by email)

Dear Madam

### **R&D Tax Incentive**


Biotron Limited (ASX: BIT) is pleased to announce that it has received an R&D Tax Incentive refund of \$1,411,944 R&D Tax Incentive refund for the 2019/20 financial year.

The R&D Tax Incentive is an Australian Government program under which companies receive cash refunds for 43.5% of eligible expenditure on research and development.

The incentive refund results from expenditure on Biotron's antiviral drug development programs.

Biotron's Managing Director, Dr Michelle Miller commented: "Whilst Biotron is fully funded for its current activities, this R&D cash rebate will strengthen the Company's cash position and support commercialisation activities."

Yours sincerely



Peter J. Nightingale  
Company Secretary

pjn10758

## **About Biotron**

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1 and promising preclinical programs for SARS-CoV-2 and Hepatitis B Virus. In addition, Biotron has several earlier stage programs designing drugs that target a class of virus protein known as viroporins which have a key role in the virus life cycle of a very broad range of viruses, many of which have caused worldwide health issues such as Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses.

## **Enquiries**

Dr Michelle Miller  
Managing Director  
Biotron Limited  
+61-(0)412313329

Rudi Michelson  
Monsoon Communications  
+61-3 9620 3333

This announcement has been approved by the Company's Managing Director.